J. Grinyo

发表

Reduced exposure to calcineurin inhibitors in renal transplantation.

P. Halloran, R. Margreiter, Y. Vanrenterghem, 2007, The New England journal of medicine.

PLACEBO-CONTROLLED STUDY OF MYCOPHENOLATE MOFETIL COMBINED WITH CYCLOSPORINE AND CORTICOSTEROIDS FOR PREVENTION OF ACUTE REJECTION

P Fauchald, Francesc Moreso, Rudolf Pichlmayr, 1995 .

Belatacept and Long-Term Outcomes in Kidney Transplantation.

L. Rostaing, H. Meier‐Kriesche, F. Vincenti, 2016, The New England journal of medicine.

Costimulation blockade with belatacept in renal transplantation.

K. Natarajan, P. Halloran, P. Lang, 2005, The New England journal of medicine.

Three‐Year Outcomes From BENEFIT‐EXT: A Phase III Study of Belatacept Versus Cyclosporine in Recipients of Extended Criteria Donor Kidneys

M. Schnitzler, R. Manfro, N. Kamar, 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Prolonged-Release Once-Daily Formulation of Tacrolimus Versus Standard-of-Care Tacrolimus in de novo Kidney Transplant Patients Across Europe

U. Maggiore, K. Budde, L. Rostaing, 2022, Transplant International.

The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy.

F. Oppenheimer, D. Kuypers, D. Hernández, 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Immunophenotype of infiltrating cells in protocol renal allograft biopsies from tacrolimus-versus cyclosporine-treated patients.

F. Moreso, D. Serón, M. Hueso, 2007, Transplantation.

Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination1, 2

F. Schena, D. Hricik, T. Gonwa, 2002, Transplantation.

The ORION Study: Comparison of Two Sirolimus‐Based Regimens versus Tacrolimus and Mycophenolate Mofetil in Renal Allograft Recipients

C. Legendre, K. Wissing, S. Steinberg, 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.

J. Squifflet, D. Abramowicz, F. Berthoux, 2000, Transplantation.

Serial Protocol Biopsies to Quantify the Progression of Chronic Transplant Nephropathy in Stable Renal Allografts

F. Moreso, D. Serón, M. Hueso, 2001, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

A Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study)

J. Campistol, J. O. Pestana, F. Vincenti, 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Novel Once‐Daily Extended‐Release Tacrolimus (LCPT) Versus Twice‐Daily Tacrolimus in De Novo Kidney Transplants: One‐Year Results of Phase III, Double‐Blind, Randomized Trial

K. Budde, L. Rostaing, K. Ciechanowski, 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial.

K. Budde, L. Rostaing, K. Ciechanowski, 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Early experience with dual kidney transplantation in adults using expanded donor criteria. Double Kidney Transplant Group (DKG).

B. Brenner, G. Remuzzi, P. Ruggenenti, 1999, Journal of the American Society of Nephrology : JASN.

Rationale for Surrogate Endpoints and Conditional Marketing Authorization of New Therapies for Kidney Transplantation

K. Budde, A. Loupy, R. Oberbauer, 2022, Transplant International.

Handling sirolimus in clinical practice

J. Morales, F. Oppenheimer, M. Arias, 2006 .

Long‐Term Exposure to Belatacept in Recipients of Extended Criteria Donor Kidneys

A. Matas, L. Rostaing, L. Pupim, 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Long‐Term Belatacept Exposure Maintains Efficacy and Safety at 5 Years: Results From the Long‐Term Extension of the BENEFIT Study

L. Rostaing, L. Pupim, F. Vincenti, 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Long‐Term Outcomes in Belatacept‐ Versus Cyclosporine‐Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT‐EXT, a Phase III Randomized Study

L. Rostaing, H. Meier‐Kriesche, A. Durrbach, 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Surrogate Endpoints for Late Kidney Transplantation Failure

K. Budde, A. Loupy, R. Oberbauer, 2022, Transplant International.

Belatacept-Based Regimens Versus a Cyclosporine A-Based Regimen in Kidney Transplant Recipients: 2-Year Results From the BENEFIT and BENEFIT-EXT Studies

N. Kamar, J. Campistol, Y. Vanrenterghem, 2010, Transplantation.

Five-year safety and efficacy of belatacept in renal transplantation.

P. Friend, P. Halloran, J. Klempnauer, 2010, Journal of the American Society of Nephrology : JASN.

A Randomized, Multicenter Study of Steroid Avoidance, Early Steroid Withdrawal or Standard Steroid Therapy in Kidney Transplant Recipients

F. Schena, R. Walker, S. Paraskevas, 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Multicenter Randomized Prospective Trial of Steroid Withdrawal in Renal Transplant Recipients Receiving Basiliximab, Cyclosporine Microemulsion and Mycophenolate Mofetil

A. Monaco, F. Vincenti, J. Grinyó, 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Minimization of Immunosuppressive Therapy After Renal Transplantation: Results of a Randomized Controlled Trial

J. Squifflet, J. Pascual, Y. Vanrenterghem, 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Cyclosporine Sparing with Mycophenolate Mofetil, Daclizumab and Corticosteroids in Renal Allograft Recipients: The CAESAR Study

B. Nashan, Y. Vanrenterghem, F. Vincenti, 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

MULTICENTER TRIAL EXPLORING CALCINEURIN INHIBITORS AVOIDANCE IN RENAL TRANSPLANTATION

B. Nashan, M. Navarro, D. Kuypers, 2001, Transplantation.

A randomized trial of basiliximab with three different patterns of cyclosporin A initiation in renal transplant from expanded criteria donors and at high risk of delayed graft function

R. Marcén, R. Lauzurica, R. Sola, 2009, Clinical transplantation.

Evaluation of pre-implantation kidney biopsies: comparison of Banff criteria to a morphometric approach.

F. Moreso, D. Serón, M. Ibernon, 2005, Kidney international.

Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials

James A. Hutchinson, A. Scheffold, J. Bluestone, 2020, The Lancet.

Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of The Transplantation Society consensus meeting.

M. Pescovitz, K. Budde, R. Walker, 2011 .

Mycophenolic Acid Exposure after Administration of Mycophenolate Mofetil in the Presence and Absence of Ciclosporin in Renal Transplant Recipients

B. Nashan, D. Kuypers, F. Vincenti, 2009, Clinical pharmacokinetics.

Pilot Randomized Study of Early Tacrolimus Withdrawal from a Regimen with Sirolimus Plus Tacrolimus in Kidney Transplantation

J. Morales, J. Campistol, M. Arias, 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

EARLY CYCLOSPORINE WITHDRAWAL FROM A SIROLIMUS-BASED REGIMEN RESULTS IN BETTER RENAL ALLOGRAFT SURVIVAL AND RENAL FUNCTION AT 48 MONTHS AFTER TRANSPLANTATION

G. Russ, A. Hartmann, J. Chapman, 2004, Transplant international : official journal of the European Society for Organ Transplantation.

Angiotensin converting enzyme genotype and chronic allograft nephropathy in protocol biopsies.

F. Moreso, D. Serón, E. Navarro, 2004, Journal of the American Society of Nephrology : JASN.

Why is organ transplantation clinically important?

Josep M Grinyó, J. Grinyó, J. Grinyo, 2013, Cold Spring Harbor perspectives in medicine.

SUBCLINICAL REJECTION IMPAIRS GLOMERULAR ADAPTATION AFTER RENAL TRANSPLANTATION.

F. Moreso, D. Serón, M. Ibernon, 2006, Kidney international.

Glomerular Size in Early Protocol Biopsies is Associated with Graft Outcome

F. Moreso, D. Serón, M. Ibernon, 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Glomerular Enlargement Assessed by Paired Donor and Early Protocol Renal Allograft Biopsies

F. Moreso, D. Serón, J. Grinyó, 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Estimation of total glomerular number in stable renal transplants.

F. Moreso, D. Serón, J. Grinyó, 2003, Journal of the American Society of Nephrology : JASN.

Structural and functional correlations in stable renal allografts.

J. Torras, F. Moreso, D. Serón, 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Quantification of interstitial chronic renal damage by means of texture analysis.

Jordi Vitrià, N. Parés, F. Moreso, 1994, Kidney international.

Role of ischemia-reperfusion injury in the development of chronic renal allograft damage.

J. Grinyo, 2001, Transplantation Proceedings.

Longitudinal study of the frequency of cytotoxic T cell precursors in kidney allograft recipients

J. Grinyó, J. Alsina, J. Bas, 1996, Clinical and experimental immunology.

Safety and efficacy of eculizumab for the prevention of antibody‐mediated rejection after deceased‐donor kidney transplantation in patients with preformed donor‐specific antibodies

G. Russ, S. Chadban, W. Marks, 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Mycophenolate-update after it has come of age.

J. Grinyó, J. Grinyo, 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

CNI sparing in de novo renal transplantation: 3-year results from the symphony study

J. Klempnauer, P. Halloran, R. Margreiter, 2008 .

Early cyclosporine withdrawal from a sirolimus‐based regimen results in better renal allograft survival and renal function at 48 months after transplantation

G. Russ, A. Hartmann, J. Chapman, 2005, Transplant international : official journal of the European Society for Organ Transplantation.

Immunosuppression with Belatacept‐Based, Corticosteroid‐Avoiding Regimens in De Novo Kidney Transplant Recipients

W. Marks, Y. Dong, E. Woodle, 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal.

N. Davies, B. Maes, H. Meier‐Kriesche, 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

BELATACEPT VS CYCLOSPORINE IN KIDNEY TRANSPLANT RECIPIENTS: TWO-YEAR OUTCOMES FROM THE BENEFIT STUDY: 1374

N. Kamar, Y. Vanrenterghem, F. Vincenti, 2010 .

Sotrastaurin, a Novel Small Molecule Inhibiting Protein Kinase C: First Clinical Results in Renal‐Transplant Recipients

K. Budde, M. Barten, C. Sommerer, 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

The Effects of FK778 in Combination With Tacrolimus and Steroids: A Phase II Multicenter Study in Renal Transplant Patients

J. Squifflet, P. Neuhaus, L. Rostaing, 2004, Transplantation.

Long-term effect of hepatitis C virus chronic infection on patient and renal graft survival.

J. Torras, F. Moreso, D. Serón, 2005, Transplantation proceedings.

Association of four DNA polymorphisms with acute rejection after kidney transplantation

K. Lindpaintner, O. Spleiss, L. Essioux, 2008, Transplant international : official journal of the European Society for Organ Transplantation.

Improved renal function, with similar proteinuria, after two years of early tacrolimus withdrawal from a regimen of sirolimus plus tacrolimus.

J. Morales, J. Campistol, M. Arias, 2008, Transplantation.

Departments of Nephrology

J. Torras, F. Moreso, O. Bestard, 2005 .

Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic.

F. Moreso, D. Serón, J. Martorell., 2007, Transplantation proceedings.

Low-dose cyclosporine with mycophenolate mofetil induces similar calcineurin activity and cytokine inhibition as does standard-dose cyclosporine in stable renal allografts.

J. Torras, D. Serón, J. Martorell., 2004, Transplantation.

An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.

S. Rodríguez de Córdoba, R. Torra, G. Ariceta, 2015, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.

Steroid sparing strategies in renal transplantation.

J. Grinyó, J. Grinyo, 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Steroid or calcineurin inhibitor-sparing immunosuppressive protocols.

J. Cruzado, J. Grinyó, J. Grinyo, 2005, Contributions to nephrology.

RAPID STEROID WITHDRAWAL VERSUS STANDARD STEROID TREATMENT IN PATIENTS TREATED WITH SIMULECT®, NEORAL®, AND CELLCEPT® FOR THE PREVENTION OF ACUTE REJECTION IN RENAL TRANSPLANTATION: A MULTICENTER, RANDOMIZED TRIAL.: Abstract# 83

A. Monaco, F. Vincenti, K. Somberg, 2000 .

Superior Outcomes in Renal Transplantation after Early Cyclosporine Withdrawal and Sirolimus Maintenance Therapy, Regardless of Baseline Renal Function

G. Russ, A. Hartmann, F. Schena, 2005, Transplantation.

An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.

S. Rodríguez de Córdoba, R. Torra, G. Ariceta, 2015, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.

Once-monthly pegylated epoetin Beta versus darbepoetin alfa every two weeks in renal transplant recipients: a randomized trial.

J. Morales, J. Campistol, M. Arias, 2013, Transplantation.

Low Serum Mannose-Binding Lectin as a Risk Factor for New Onset Diabetes Mellitus After Renal Transplantation

J. Fernández-Real, W. Ricart, F. Moreso, 2009, Transplantation.

Immunosuppression in the era of biological agents.

J. Torras, J. Cruzado, O. Bestard, 2012, Advances in experimental medicine and biology.

Hepatitis C virus-associated membranoproliferative glomerulonephritis in renal allografts.

J. Torras, J. Grinyó, D. Serón, 1996, Journal of the American Society of Nephrology : JASN.

Donor age and delayed graft function as predictors of renal allograft survival in rejection-free patients.

F. Moreso, D. Serón, J. Grinyó, 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Depleting effect of antithymocyte globulin on T-lymphocyte subsets in kidney transplantation.

J. Grinyó, J. Alsina, J. Bas, 1999, Transplantation proceedings.

Belatacept-Based Regimens Are Associated With Improved Cardiovascular and Metabolic Risk Factors Compared With Cyclosporine in Kidney Transplant Recipients (BENEFIT and BENEFIT-EXT Studies)

H. Neumayer, P. Lang, J. Campistol, 2011, Transplantation.

Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function.

D. Serón, I. Sabaté, J. Grinyó, 1998, Transplantation.

Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical Trial

J. D. de Fijter, A. Hartmann, A. V. van Zonneveld, 2022, Kidney medicine.

Ten‐year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4‐weekly or 8‐weekly

H. Meier‐Kriesche, F. Vincenti, C. Larsen, 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.

R. Manfro, N. Kamar, F. Vincenti, 2017, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2‐year results from the long‐term extension of a phase II study

Dolca Thomas, R. Manfro, N. Kamar, 2012, Transplant international : official journal of the European Society for Organ Transplantation.

Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study.

Dolca Thomas, L. Rostaing, F. Vincenti, 2011, Clinical journal of the American Society of Nephrology : CJASN.

Reverse dipper pattern of blood pressure at 3 months is associated with inflammation and outcome after renal transplantation.

J. Fernández-Real, W. Ricart, F. Moreso, 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Effect of pravastatin in the treatment of hypercholesterolemia after renal transplantation under cyclosporine and prednisone.

M. J. Castiñeiras, J. Torras, D. Serón, 1995, Transplantation proceedings.

Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantation.

F. Moreso, D. Serón, J. Cruzado, 2005, Transplantation proceedings.

F. Oppenheimer, D. Hernández, H. Ekberg, 2009, Transplantation.

Calcineurin Inhibitor Minimization in the Symphony Study: Observational Results 3 Years after Transplantation

P. Halloran, Y. Vanrenterghem, H. Tedesco-Silva, 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Beneficial effect of concomitant induction with antilymphoblast globulin, cyclosporine, and steroids on long-term renal allograft outcome.

F. Moreso, D. Serón, J. Cruzado, 2004, Transplantation Proceedings.

CNI SPARING WITH MYCOPHENOLATE MOFETIL IN DE NOVO RENAL TRANSPLANTATION: 3-YEAR RESULTS FROM THE SYMPHONY STUDY: 623

J. Klempnauer, P. Halloran, R. Margreiter, 2008 .

POPULATION PHARMACOKINETICS OF MYCOPHENOLIC ACID IN COMBINATION WITH FREE OR REDUCED DOSES OF CALCINEURIN INHIBITORS DURING THE FIRST WEEK IN RENAL TRANSPLANT: THE SYMPHONY STUDY: 105

H. Colom, I. Trocóniz, F. Oppenheimer, 2008 .

COST-EFFECTIVENESS ANALYSIS OF ADVERSE EVENTS IN LOW TOXICITY IMMUNOSUPPRESSIVE REGIMENS. PRELIMINARY RESULTS OF THE QUALITY OF LIFE SUBSTUDY WITHIN THE SYMPHONY STUDY.: 107

F. Oppenheimer, D. Hernández, H. Ekberg, 2008 .

Pharmacokinetics of total and free mycophenolic acid in renal transplantation receiving standard-dose cyclosporine, low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: The symphony PK sub-study

F. Oppenheimer, D. Hernández, H. Ekberg, 2007 .

The use of mycophenolate mofetil, daclizumab and corticosteroids with cyclosporine (low dose, low dose/withdrawal and standard dose) to optimize renal function in renal allograft recipients - 18 month results

E. Calleja, B. Nashan, Y. Vanrenterghem, 2005 .

THE USE OF DACLIZUMAB AND MYCOPHENOLATE MOFETIL IN COMBINATION WITH CORTICOSTEROIDS AND CYCLOSPORINE (LOW DOSE VERSUS LOW DOSE FOLLOWED BY WITHDRAWAL) TO OPTIMIZE RENAL FUNCTION IN RECIPIENTS OF RENAL ALLOGRAFTS

E. Calleja, B. Nashan, Y. Vanrenterghem, 2004 .

Peripheral blood lymphoid subsets and long-term clinical course of kidney recipients: a longitudinal study.

M. Corominas, J. Grinyó, J. Alsina, 1998, Cytometry.

Rapid steroid withdrawal versus standard steroid therapy in patients treated with basiliximab, cyclosporine, and mycophenolate mofetil for the prevention of acute rejection in renal transplantation.

A. Monaco, F. Vincenti, K. Somberg, 2001, Transplantation proceedings.

Graft dysfunction and cardiovascular risk--an un-holy alliance.

F. Moreso, J. Grinyó, J. Grinyo, 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Renal allograft performance in immigrant transplant recipients

J. Grinyo, 2020, Transplant International.

Differential impact of belatacept and cyclosporine A on central aortic blood pressure and arterial stiffness after renal transplantation

T. Westhoff, W. Zidek, N. Pagonas, 2014, Clinical transplantation.

Intragraft expression of the IL-10 gene is up-regulated in renal protocol biopsies with early interstitial fibrosis, tubular atrophy, and subclinical rejection.

F. Moreso, D. Serón, F. O'Valle, 2010, The American journal of pathology.

Interaction Between Everolimus and Tacrolimus in Renal Transplant Recipients: A Pharmacokinetic Controlled Trial

J. Pascual, M. Cabello, M. Brunet, 2010, Transplantation.

Reliability of chronic allograft nephropathy diagnosis in sequential protocol biopsies.

F. Moreso, D. Serón, M. Hueso, 2002, Kidney international.

Evaluation of biopsy changes in the early diagnosis of chronic transplant nephropathy

E. Condom, F. Moreso, D. Serón, 1997 .

Longterm allograft outcome in patients treated with prophylactic antilymphocyte globulin or OKT3 as induction therapy in cadaveric kidney transplantation

J. Torras, F. Moreso, D. Serón, 1997 .

Renal involvement in non-malignant IgM gammopathy.

A. Domingo, R. Poveda, J. Grinyó, 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Open letter to Bristol Myers Squibb: belatacept; we aren't done yet.

A. Kirk, L. Rostaing, F. Vincenti, 2023, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Calculated cardiovascular risk after conversion from calcineurin inhibitor to belatacept in kidney transplant recipients: A randomized controlled trial

A. Hartmann, A. Jardine, H. Holdaas, 2022 .

Donor structural and functional parameters are independent predictors of renal function at 3 months.

J. Torras, F. Moreso, D. Serón, 2007, Transplantation proceedings.

Belatacept: from rational design to clinical application

T. Wekerle, J. Grinyó, J. Grinyo, 2012, Transplant international : official journal of the European Society for Organ Transplantation.

IMMUNOSUPPRESSION WITH BELATACEPT-BASED, CNI-AVOIDING AND STEROID-AVOIDING REGIMENS VS A TACROLIMUS-BASED, STEROID-AVOIDING REGIMEN IN KIDNEY TRANSPLANT PATIENTS: RESULTS OF A 1-YEAR, RANDOMIZED STUDY: 1436

W. Marks, Y. Dong, E. Woodle, 2010 .

SAFETY PROFILE OF BELATACEPT IN KIDNEY TRANSPLANT RECIPIENTS FROM A POOLED ANALYSIS OF PHASE II AND PHASE III STUDIES: 1417

Dolca Thomas, Y. Vanrenterghem, F. Vincenti, 2010 .

BELATACEPT VS CYCLOSPORINE IN ECD KIDNEY TRANSPLANTS: TWO-YEAR OUTCOMES FROM THE BENEFIT-EXT STUDY: 1394

Y. Vanrenterghem, F. Vincenti, C. Larsen, 2010 .

SWITCH FROM A CNI- TO A BELATACEPT-BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRANSPLANT RECIPIENTS IS SAFE AND RESULTS IN BETTER RENAL FUNCTION: 12 MONTH RESULTS FROM A PHASE II STUDY: 1446

Dolca Thomas, L. Rostaing, F. Vincenti, 2010 .

TGF-beta(1) gene expression in protocol biopsies from patients with stable renal allograft function.

F. Moreso, D. Serón, M. Hueso, 2001, Transplantation proceedings.

Relationship Between Subclinical Rejection and Genotype, Renal Messenger RNA, and Plasma Protein Transforming Growth Factor–β1 Levels

F. Moreso, D. Serón, E. Navarro, 2006, Transplantation.

Primary outcomes from a randomized, Phase III study of belatacept vs cyclosporine in ECD kidney transplants (BENEFIT-EXT Study)

Christian P. Larsen, Sander Florman, Y. Vanrenterghem, 2009 .

Primary Outcomes from a Randomized, Phase III Study of Belatacept vs Cyclosporine in Kidney Transplant Recipients (BENEFIT Study)

L. Rostaing, Y. Vanrenterghem, F. Vincenti, 2009 .

Impact of long-term therapy with FTY720 or mycophenolate mofetil on cardiac conduction and rhythm in stable adult renal transplant patients.

S. Mulgaonkar, A. Jardine, R. Walker, 2007, Transplantation.

Lipid-lowering long-term effects of six different statins in hypercholesterolemic renal transplant patients under cyclosporine immunosuppression.

M. J. Castiñeiras, A. Martínez‐Castelao, D. Serón, 2002, Transplantation proceedings.

Revisiting double kidney transplantation: two kidneys provide better graft survival than one.

J. Torras, J. Cruzado, O. Bestard, 2011, Transplantation proceedings.

Early sirolimus use with cyclosporine elimination does not induce progressive proteinuria.

J. Morales, J. Campistol, M. Arias, 2007, Transplantation proceedings.

Clinical approach to kidney disease in kidney recipients in Spain.

J. Grinyó, Á. Gutiérrez-Dalmau, J. Campistol, 2015, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.

Clinical assessment and determinants of chronic allograft nephropathy in maintenance renal transplant patients.

J. Grinyó, J. Campistol, N. Saval, 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Histologic findings in protocol biopsies performed in stable renal allografts under different immunosuppressive schedules.

F. Moreso, D. Serón, M. Ibernon, 2003, Transplantation proceedings.

Sirolimus use in de "novo renal" transplantation.

J. Morales, F. Oppenheimer, M. Arias, 2006, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.

Treatment of idiopathic membranous nephropathy with the combination of steroids, tacrolimus and mycophenolate mofetil: results of a pilot study.

F. Calero, L. Pérez, R. Poveda, 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2‐year results from the long‐term extension of a phase II study

Dolca Thomas, R. Manfro, N. Kamar, 2012, Transplant international : official journal of the European Society for Organ Transplantation.

Double-blind, crossover, comparative study of doxazosin and enalapril in the treatment of hypertension in renal transplant patients under cyclosporine immunosuppression.

A. Martínez‐Castelao, M. Hueso, J. Rejas, 2002, Transplantation proceedings.

Allograft Function as Endpoint for Clinical Trials in Kidney Transplantation

K. Budde, D. Hesselink, F. Diekmann, 2022, Transplant International.

Prevention and management of late renal allograft dysfunction.

F. Moreso, D. Serón, J. Grinyo, 2001, Journal of nephrology.

Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of The Transplantation Society consensus meeting.

M. Pescovitz, K. Budde, R. Walker, 2011, Transplantation reviews.

Baseline Immunosuppression is Associated with Histological Findings in Early Protocol Biopsies

F. Moreso, D. Serón, J. Cruzado, 2004, Transplantation.